Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Neurology · MELAS Syndrome

What is the Life Expectancy for MELAS Syndrome?

At a Glance

Life expectancy for MELAS syndrome varies widely depending on age of onset and mutation levels. While childhood-onset typically progresses faster, proactive management of neurological and cardiac complications at a specialized mitochondrial center can significantly improve quality of life.

In this answer

3 sections

01

How Heteroplasmy Affects Disease Progression

02

Primary Causes of Mortality and Warning Signs

03

The Role of Proactive Management

The life expectancy for someone diagnosed with MELAS syndrome varies significantly from person to person, making it difficult to predict an exact timeframe. Because MELAS is a highly variable and progressive condition, survival depends heavily on the age at which symptoms first appear and which organs are most affected [1][2].

For children and young adults who develop symptoms early in life (juvenile-onset), the disease tends to progress more rapidly. Recent studies looking at pediatric patients report that approximately 65.3% of children survive 10 years after their initial diagnosis, and about 34.5% survive for 15 years [3]. While these statistics can be frightening, it is important to understand that no single number applies to everyone.

For adults who develop symptoms later in life, the disease course often looks different. Adult-onset MELAS may present with fewer severe stroke-like episodes and more issues related to hearing loss, diabetes, or muscle weakness [4]. Regardless of when symptoms begin, proactive, specialized care can help manage the condition and improve the quality of daily life [5][6].

How Heteroplasmy Affects Disease Progression

MELAS is most commonly caused by a specific genetic mutation in the mitochondrial DNA (often the m.3243A>G mutation). Because each cell contains many mitochondria, a person with MELAS has a mixture of both healthy and mutated mitochondria—a concept known as heteroplasmy [7]. Since mitochondrial DNA is inherited from the mother, genetic counseling is highly recommended so that maternal relatives can understand their own risks.

The percentage of mutated mitochondria (the “mutation load”) plays a significant role in how the disease progresses:

  • Higher heteroplasmy levels generally correlate with a more severe disease burden and an earlier onset of symptoms [8][9].
  • Tissue-specific differences mean that the mutation level in the blood might not match the mutation level in muscles or the brain. Blood tests alone are an unreliable predictor of a person’s exact future because blood mutation levels can decline with age [10][11].
  • Other individual genetic differences influence how fast the disease progresses, which is why two people with the same mutation load can have very different experiences [12][7].

Primary Causes of Mortality and Warning Signs

Understanding the main risks associated with MELAS can help patients and families know what emergencies to watch out for. The most common causes of shortened life expectancy include:

  • Neurological Complications: Severe stroke-like episodes (periods where the brain acts like it is having a stroke, but without a blocked blood vessel) are a hallmark of the disease [13]. Complications from these episodes, or continuous and difficult-to-treat seizures (status epilepticus), are leading causes of mortality [14][15].
    • Warning Signs: Seek immediate emergency care for severe, sudden headaches with vomiting, vision changes, confusion, new muscle weakness on one side of the body, or seizures.
  • Cardiopulmonary Failure: The heart is an energy-demanding organ often affected by mitochondrial dysfunction. Cardiomyopathy (disease of the heart muscle), heart failure, and sudden cardiac death are critical risks that significantly impact prognosis [16][17][18].
  • Metabolic and Systemic Issues: Severe lactic acidosis (a dangerous build-up of lactic acid in the blood) and multi-organ failure can also contribute to life-threatening emergencies [3][15].
    • Warning Signs: Extreme, unexplained fatigue, persistent nausea and vomiting, rapid or shallow breathing, and severe muscle pain.

The Role of Proactive Management

While there is currently no cure for MELAS, a multidisciplinary approach is essential for optimizing quality of life. Whenever possible, patients should connect with a specialized mitochondrial medicine center or neurogenetics clinic, as general specialists may lack experience managing MELAS [5][19].

  • Routine Screenings: Regular monitoring for cardiac issues through echocardiograms and ECGs can catch heart problems early [17][20]. Routine checks for diabetes and hearing loss allow for early intervention [21][22].
  • Symptom Management: Working closely with a neurologist to manage seizures and treat stroke-like episodes is a priority. Intravenous (IV) L-arginine is widely used in hospitals as a standard emergency treatment for acute stroke-like episodes, while oral L-arginine is often prescribed daily to help reduce their frequency, though research on its long-term effectiveness is ongoing [23][24].
    • CRITICAL WARNING: Patients with mitochondrial diseases must avoid certain anti-seizure medications—specifically valproic acid (Depakote)—which can be highly toxic and trigger fatal liver failure in people with mitochondrial disease.
  • Quality of Life and Avoiding Triggers: A key part of living with MELAS is avoiding “metabolic triggers” that demand more energy than the mitochondria can produce [25][6]. These dangerous triggers include:
    • Prolonged fasting or dehydration
    • Extreme physical exertion
    • Acute infections or illnesses (which should be treated aggressively)
    • Severe physiological or psychological stress

By managing energy levels, avoiding these metabolic triggers, and coordinating care among specialized providers, patients can better manage symptoms and focus on living as fully and comfortably as possible.

Common questions in this guide

How long can someone live with MELAS syndrome?
Life expectancy varies widely based on the age symptoms begin and the severity of organ involvement. While the disease tends to progress more rapidly when symptoms start in childhood, early diagnosis and proactive care at a specialized mitochondrial center can help manage symptoms and improve daily life.
What are the main causes of mortality in MELAS?
The primary life-threatening risks include severe neurological complications like stroke-like episodes and continuous seizures. Heart issues, such as cardiomyopathy and heart failure, along with severe lactic acidosis, are also leading causes of mortality.
How does heteroplasmy affect my MELAS prognosis?
Heteroplasmy refers to the mixture of healthy and mutated mitochondria in a person's cells. Generally, a higher percentage of mutated mitochondria results in earlier symptom onset and a more severe disease course, though individual experiences can still vary greatly.
Are there anti-seizure medications someone with MELAS should avoid?
Yes. Patients with MELAS and other mitochondrial diseases must strictly avoid valproic acid (Depakote), a common anti-seizure medication. This drug can be highly toxic and trigger fatal liver failure in individuals with mitochondrial dysfunction.
What are the warning signs of a stroke-like episode?
You should seek immediate emergency medical care if you experience severe, sudden headaches accompanied by vomiting, vision changes, confusion, seizures, or new muscle weakness on one side of your body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current symptoms and test results, how would you characterize my disease progression compared to typical adult-onset or pediatric MELAS?
  2. 2.Are my current anti-seizure medications safe for someone with a mitochondrial disease, and have we ensured valproic acid is strictly avoided?
  3. 3.Should I be carrying an emergency protocol letter for local hospitals that details standard treatments, like IV L-arginine, for when I have a stroke-like episode or lactic acidosis?
  4. 4.Can you refer me to a specialized mitochondrial medicine center or a genetic counselor to help coordinate my multidisciplinary care?
  5. 5.What specific early warning signs for cardiac complications or lactic acidosis should prompt me to go straight to the emergency room?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What Medications Should You Avoid with MELAS Syndrome?Is MELAS Syndrome Hereditary and Passed to Children?How Is a MELAS Stroke Different from a Regular Stroke?Why Does MELAS Syndrome Cause Diabetes? (MIDD Explained)Why is Fasting Dangerous with MELAS Syndrome?Can MELAS Cause Severe Stomach Pain & Constipation?Does MELAS Syndrome Cause Hearing Loss?What is a MELAS Mitochondrial Cocktail?Why is My Genetic Blood Test Negative for MELAS?

References

References (25)
  1. 1

    Haemorrhagic Transformation of a MELAS Stroke-Like Lesion.

    Bensaidane MR, Camden MC, Savard M

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2020; (47(1)):117-118 doi:10.1017/cjn.2019.317.

    PMID: 31648660
  2. 2

    Pathogenic mitochondrial DNA 3243A>G mutation: From genetics to phenotype.

    Li D, Liang C, Zhang T, et al.

    Frontiers in genetics 2022; (13()):951185 doi:10.3389/fgene.2022.951185.

    PMID: 36276941
  3. 3

    Clinical characteristics and long-term prognosis of 150 children with MELAS syndrome in China.

    Xu C, Dai S, Jiang H, et al.

    Journal of neurology 2025; (272(4)):280 doi:10.1007/s00415-025-13009-z.

    PMID: 40119058
  4. 4

    Neurological manifestations in adult patients with the m.3243A>G variant in mitochondrial DNA.

    Majamaa K, Kärppä M, Moilanen JS

    BMJ neurology open 2024; (6(2)):e000825 doi:10.1136/bmjno-2024-000825.

    PMID: 39324021
  5. 5

    Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes.

    Fan HC, Lee HF, Yue CT, Chi CS

    Life (Basel, Switzerland) 2021; (11(11)) doi:10.3390/life11111111.

    PMID: 34832987
  6. 6

    Acute Management of Neurological Events in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome: A Case Report.

    Aladashvili Z, Rodriguez TB, Izquierdo-Pretel G

    Cureus 2025; (17(5)):e83959 doi:10.7759/cureus.83959.

    PMID: 40502899
  7. 7

    Heteroplasmy and phenotype spectrum of the mitochondrial tRNALeu (UUR) gene m.3243A>G mutation in seven Han Chinese families.

    Liu G, Shen X, Sun Y, et al.

    Journal of the neurological sciences 2020; (408()):116562 doi:10.1016/j.jns.2019.116562.

    PMID: 31722256
  8. 8

    Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors.

    Pickett SJ, Grady JP, Ng YS, et al.

    Annals of clinical and translational neurology 2018; (5(3)):333-345 doi:10.1002/acn3.532.

    PMID: 29560378
  9. 9

    Clinical Characteristics of Diabetes in People with Mitochondrial DNA 3243A>G Mutation in Korea.

    Rho EH, Baek SI, Lee H, et al.

    Diabetes & metabolism journal 2024; (48(3)):482-486 doi:10.4093/dmj.2023.0078.

    PMID: 38311059
  10. 10

    Phenotypic Heterogeneity in 5 Family Members with the Mitochondrial Variant m.3243A>G.

    Finsterer J, Laccone F

    The American journal of case reports 2020; (21()):e927938 doi:10.12659/AJCR.927938.

    PMID: 33237887
  11. 11

    Lecocytes mutation load declines with age in carriers of the m.3243A>G mutation: A 10-year Prospective Cohort.

    Langdahl JH, Larsen M, Frost M, et al.

    Clinical genetics 2018; (93(4)):925-928 doi:10.1111/cge.13201.

    PMID: 29266179
  12. 12

    Contribution of nuclear and mitochondrial gene mutations in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome.

    Chakrabarty S, Govindaraj P, Sankaran BP, et al.

    Journal of neurology 2021; (268(6)):2192-2207 doi:10.1007/s00415-020-10390-9.

    PMID: 33484326
  13. 13

    Stroke-like episodes, peri-episodic seizures, and MELAS mutations.

    Finsterer J, Wakil SM

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2016; (20(6)):824-829 doi:10.1016/j.ejpn.2016.08.002.

    PMID: 27562097
  14. 14

    Long-term prognostic factors and outcomes in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes: a clinical and biochemical marker analysis.

    Gao R, Gu L, Zuo W, Wang P

    Frontiers in neurology 2024; (15()):1491283 doi:10.3389/fneur.2024.1491283.

    PMID: 39697439
  15. 15

    Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) Syndrome: Frequency, Clinical Features, Imaging, Histopathologic, and Molecular Genetic Findings in a Third-level Health Care Center in Mexico.

    Galnares-Olalde JA, López-Hernández JC, Benitez-Alonso EO, et al.

    The neurologist 2021; (26(4)):143-148 doi:10.1097/NRL.0000000000000331.

    PMID: 34190208
  16. 16

    Cardiac manifestations in adult MELAS syndrome (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome)- a cross-sectional study.

    Stoevesandt D, Schlitt A, Röntgen P, Kraya T

    Orphanet journal of rare diseases 2025; (20(1)):62 doi:10.1186/s13023-025-03534-5.

    PMID: 39930534
  17. 17

    MELAS Syndrome with Cardiac Involvement: A Multimodality Imaging Approach.

    Seitun S, Massobrio L, Rubegni A, et al.

    Case reports in cardiology 2016; (2016()):1490181 doi:10.1155/2016/1490181.

    PMID: 27891257
  18. 18

    The MELAS mutation m.3243A>G promotes reactivation of fetal cardiac genes and an epithelial-mesenchymal transition-like program via dysregulation of miRNAs.

    Meseguer S, Panadero J, Navarro-González C, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2018; (1864(9 Pt B)):3022-3037 doi:10.1016/j.bbadis.2018.06.014.

    PMID: 29928977
  19. 19

    Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic.

    Pröbstel AK, Schaller A, Lieb J, et al.

    Neurology. Genetics 2016; (2(6)):e121 doi:10.1212/NXG.0000000000000121.

    PMID: 27878137
  20. 20

    A Case Report of a Clinically Suspected Diagnosis of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome With Cardiac Impairment.

    Momoh R, Kollamparambil S

    Cureus 2024; (16(3)):e56980 doi:10.7759/cureus.56980.

    PMID: 38665734
  21. 21

    Endocrine disorders in a patient with a suspicion of a mitochondrial disease, MELAS syndrome - a case report and literature review.

    Baszyńska-Wilk M, Moszczyńska E, Szarras-Czapnik M, et al.

    Pediatric endocrinology, diabetes, and metabolism 2021; (27(3)):213-218 doi:10.5114/pedm.2021.107713.

    PMID: 34596368
  22. 22

    MELAS Presenting as Bilateral Symmetric Occipital and Temporal Cortices Lesions: A Case Report and Literature Review.

    Liu Q, Wang Z, Shi J, et al.

    The neurologist 2025; (30(2)):75-79 doi:10.1097/NRL.0000000000000588.

    PMID: 39450883
  23. 23

    l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review.

    Stefanetti RJ, Ng YS, Errington L, et al.

    Neurology 2022; (98(23)):e2318-e2328 doi:10.1212/WNL.0000000000200299.

    PMID: 35428733
  24. 24

    MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.

    El-Hattab AW, Adesina AM, Jones J, Scaglia F

    Molecular genetics and metabolism 2015; (116(1-2)):4-12.

    PMID: 26095523
  25. 25

    Outcomes misaligned in mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): implications for trial design.

    Stefanetti RJ, Charman SJ, Newman J, et al.

    Brain communications 2025; (7(5)):fcaf342 doi:10.1093/braincomms/fcaf342.

    PMID: 41048545

This page provides educational information about MELAS syndrome life expectancy and prognosis. It is not a substitute for professional medical advice from your neurologist or mitochondrial medicine specialist.

Get notified when new evidence is published on MELAS.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.